

Chapter 22

Cancer survival in Seoul, Republic of Korea, 1993–1997

Ahn YO and Shin MH

Abstract

The Seoul cancer registry was established in 1991. Cancer is a notifiable disease, and registration of cases is done by passive and active methods. The registry contributed survival data for 56 cancer sites or types registered during 1993–1997. Follow-up information has been gleaned predominantly by passive methods with median follow-up ranging between 5–82 months for various cancers. The proportion with histologically verified diagnosis for different cancers ranged between 23–99%; death certificates only (DCOs) comprised 0–67%; 33–100% of total registered cases were included for survival analysis. The top-ranking cancers on 5-year age-standardized relative survival rates were testis and placenta (95%), thyroid (93%), non-melanoma skin (93%), corpus uteri (79%), renal pelvis (77%), cervix (76%), Hodgkin lymphoma (75%), breast (74%) and prostate (74%). Five-year relative survival by age group showed a decreasing trend with increasing age groups for cancers of the small intestine, colon, gall bladder, cervix, corpus uteri, ovary, kidney, urinary bladder and thyroid, or was fluctuating for other cancers.

Seoul cancer registry

The Seoul cancer registry was established in 1991 at the Seoul National University College of Medicine, Seoul, funded by the Ministry of Health and Welfare. The registry contributed data to the quinquennial IARC publication *Cancer Incidence in Five Continents* for the first time in volume VIII [1]. Cancer is a notifiable disease, and registration of cases is done by passive and active methods. The principal source of information on 80% of cancer cases is the data file from Korean central cancer registry. The rest of the cases are registered by the active method of visiting more than 60 smaller hospitals besides perusal of Korean medical insurance records. The registry covers an area of 605.5 km² and caters to an entirely metropolitan population of about 10.6 million with a sex ratio of 1010 females to 1000 males in 1995. The average annual age-standardized incidence rate is 287 per 100 000 among males and 173 per 100 000 among females, with a lifetime cumulative risk of one in 4 of developing cancer in the period 1993–1997. The common cancers among males are stomach, liver and lung. The rank order among females is stomach, cervix and breast [1].

The registry is contributing data on survival from 56 cancer sites or types registered during 1993–1997 for the first time in this volume of IARC publication on *Cancer Survival in Africa, Asia, the Caribbean and Central America*.

Data quality indices (Table 1)

The proportion of cases with histologically verified cancer diagnosis in the series is 71%, varying from 22% (cancer of the uterus unspecified) to 99% (Hodgkin lymphoma). The proportion of cases registered as death certificates only (DCOs) is 9%, ranging from none for a few cancers (lip, vagina, penis, Hodgkin lymphoma and multiple myeloma) to 67% in unspecified uterus cancer. Cases excluded without any follow-up are 6%. Thus, 33–100% of the total cases registered are included in the estimation of the survival probability.

Outcome of follow-up (Table 2)

The follow-up information has been obtained predominantly by passive methods. These included obtaining mortality information from the death certificates in the national statistics office. The mortality data are periodically matched with the incident cancer database using the National Identity number issued by the Korean government to every citizen at birth. The vital status of the unmatched incident cases is also ascertained by repeated scrutiny of hospital records. However, all incident cases for whom death information is not available are presumed to be alive on the last date of the year for which the mortality data are fully utilized for matching.


The closing date of follow-up was 31st December 2001. The median follow-up ranged from 5 months for cancer of the pancreas to 82 months for cancer of the placenta.

Survival statistics

All ages and both sexes together (Table 3)

The top-ranking cancers on 5-year relative survival are thyroid (95%), testis (94%), placenta and non-melanoma skin (93%) and corpus uteri (85%). The lowest survival rate is encountered with pancreatic cancer and unspecified leukaemia (15%) preceded by lung, liver and oesophagus (19%). Larynx (72%) and salivary gland (69%), among other head and neck cancers, and colon (64%) and rectum (61%), among gastrointestinal cancers, have higher survival than others. Survival from cancers of the urinary system ranged between 76% for urinary bladder and 43% for unspecified category. Hodgkin lymphoma had a better survival (74%) than non-Hodgkin (57%). The survival figures for leukaemias are 43% for lymphoid and 27% for myeloid.

Figure 1a. Top ten cancers (ranked by survival), Seoul, Republic of Korea, 1993–1997




The 5-year age-standardized relative survival (ASRS) probability for all ages together is generally less than or similar to the corresponding unadjusted one for a majority of cancers. Also, the 5-year ASRS (0–74 years of age) is generally higher than or similar to the corresponding ASRS (all ages) for a majority of cancers.

Sex Male (Table 4a)

The 5-year relative survival probabilities for lip, larynx, renal pelvis, bladder and unspecified urinary system cancers are noticeably higher among males than females.


Figure 1b. Top five cancers (ranked by survival), Male, Seoul, Republic of Korea, 1993–1997



Female (Table 4a)

The 5-year relative survival estimates for cancers of the breast, cervix and ovary are 80%, 79% and 66%, respectively. Survival is distinctly higher among females than males for cancers of the oral cavity, salivary gland, nasopharynx, nose/sinuses, other thoracic organs, skin melanoma and non-melanoma, mesothelioma, Hodgkin lymphoma and lymphoid leukaemia.

Figure 1c. Top five cancers (ranked by survival), Female, Seoul, Republic of Korea, 1993–1997



Age group (Table 4b)

The 5-year relative survival by age group reveals an inverse relationship: a decreasing survival with increasing age at diagnosis for cancers of the small intestine, colon, gall bladder, cervix, corpus uteri, ovary, kidney, urinary bladder and thyroid. For all other cancers, the survival by age group did not display any pattern.

References

1. Parkin DM, Whelan SL, Ferlay J and Storm H. *Cancer Incidence in Five Continents, Vol I to VIII: IARC Cancerbase No. 7*. IARCPRESS, Lyon, 2005.

Site	ICD-10	Total registered	%		Excluded cases			Included cases	
			HV	DCO	DCO	Follow-up	Others	Total	%
Lip	C00	26	88.5	0.0	0	0	0	0	0.0
Tongue	C01-02	268	83.6	6.0	16	9	0	25	9.3
Oral cavity	C03-06	344	80.2	8.4	29	12	0	41	11.9
Salivary gland	C07-08	204	89.7	1.0	2	8	0	10	4.9
Tonsil	C09	98	86.7	1.0	1	5	0	6	6.1
Oropharynx	C10	57	75.4	3.5	2	3	0	5	8.8
Nasopharynx	C11	295	81.7	0.7	2	15	0	17	5.8
Hypopharynx	C12-13	180	86.1	3.9	7	3	0	10	5.6
Oesophagus	C15	1 353	72.8	10.6	143	76	0	219	16.2
Stomach	C16	18 914	77.9	9.0	1710	1021	3	2734	14.5
Small intestine	C17	284	75.4	7.7	22	20	0	42	14.8
Colon	C18	4 277	79.1	7.3	314	243	0	557	13.0
Rectum	C19-20	4 071	87.9	2.8	112	243	1	356	8.7
Anus	C21	420	37.1	21.2	89	18	0	107	25.5
Liver	C22	12 120	24.3	13.3	1611	635	2	2248	18.5
Gall bladder	C23-24	2 751	51.9	11.7	321	137	0	458	16.6
Pancreas	C25	2 284	38.2	15.6	356	121	0	477	20.9
Gastrointestinal tract	C26	174	10.3	65.5	114	2	0	116	66.7
Nose/Sinuses	C30-31	246	85.4	4.5	11	11	0	22	8.9
Larynx	C32	956	75.5	12.7	121	44	0	165	17.3
Lung	C33-34	10 294	67.8	12.7	1311	499	2	1812	17.6
Other thoracic organs	C37-38	265	74.3	10.6	28	11	0	39	14.7
Bone	C40-41	424	74.5	11.3	48	27	6	81	19.1
Melanoma of skin	C43	199	93.0	2.5	5	15	0	20	10.1
Other skin	C44	719	89.7	5.7	41	59	1	101	14.0
Mesothelioma	C45	56	87.5	1.8	1	3	0	4	7.1
Connective tissue	C47+C49	542	86.9	4.6	25	32	1	58	10.7
Peritoneum	C48	180	76.7	5.6	10	10	0	20	11.1
Breast	C50	5 907	88.3	3.3	196	356	0	552	9.3
Vulva	C51	59	93.2	1.7	1	3	0	4	6.8
Vagina	C52	53	94.3	0.0	0	7	0	7	13.2
Cervix	C53	5 861	88.2	2.0	119	381	4	504	8.6
Corpus uteri	C54	571	94.7	0.5	3	46	0	49	8.6
Uterus unspecified	C55	267	22.8	66.7	178	2	0	180	67.4
Ovary	C56	1 451	87.3	2.8	40	104	2	146	10.1
Other female genital org.	C57	119	39.5	26.1	31	3	0	34	28.6
Placenta	C58	121	40.5	2.5	3	5	0	8	6.6
Penis	C60	47	97.9	0.0	0	4	0	4	8.5
Prostate	C61	1 051	81.3	4.7	49	54	0	103	9.8
Testis	C62	121	91.7	3.3	4	10	1	15	12.4
Kidney	C64	1 302	81.6	4.5	59	66	0	125	9.6
Renal pelvis	C65	155	94.2	0.6	1	7	0	8	5.2
Ureter	C66	117	91.5	1.7	2	11	0	13	11.1
Urinary bladder	C67	2 153	85.6	5.2	112	110	1	223	10.4
Other urinary organs	C68	104	34.6	33.7	35	5	0	40	38.5
Eye	C69	104	73.1	5.8	6	5	0	11	10.6
Brain & nervous system	C70-72	1 570	57.8	19.4	304	103	0	407	25.9
Thyroid	C73	2 883	93.8	1.5	43	183	0	226	7.8
Adrenal gland	C74	103	65.0	10.7	11	5	0	16	15.5
Other endocrine	C75	107	44.9	20.6	22	7	0	29	27.1
Hodgkin lymphoma	C81	144	99.3	0.0	0	11	0	11	7.6
Non-Hodgkin lymphoma	C82-85+C96	1 872	92.7	4.2	79	113	0	192	10.3
Multiple myeloma	C90	375	93.9	0.0	0	28	0	28	7.5
Lymphoid leukaemia	C91	641	98.6	1.2	8	38	0	46	7.2
Myeloid leukaemia	C92-94	1 336	96.6	2.8	38	79	0	117	8.8
Leukaemia unspecified	C95	166	42.2	45.8	76	10	0	86	51.8
									80
									48.2

HV: histologically verified; DCO: death certificate only

Table 2. Number and proportion of cases by vital status and median follow-up (in months) by site: Seoul, Republic of Korea, 1993–1997 cases followed-up until 2001

Site	ICD-10	Cases included	Dead		Alive		Complete FU		Median FU (in months)
			No.	%	No.	%	No.	%	
Lip	C00	26	13	50.0	13	50.0	26	100.0	46.0
Tongue	C01-02	243	115	47.3	128	52.7	243	100.0	54.4
Oral cavity	C03-06	303	169	55.8	134	44.2	303	100.0	36.2
Salivary gland	C07-08	194	71	36.6	123	63.4	194	100.0	62.5
Tonsil	C09	92	47	51.1	45	48.9	92	100.0	52.4
Oropharynx	C10	52	36	69.2	16	30.8	52	100.0	21.9
Nasopharynx	C11	278	164	59.0	114	41.0	278	100.0	40.4
Hypopharynx	C12-13	170	129	75.9	41	24.1	170	100.0	15.1
Oesophagus	C15	1 134	947	83.5	187	16.5	1 134	100.0	9.2
Stomach	C16	16 180	9 354	57.8	6 826	42.2	16 180	100.0	28.3
Small intestine	C17	242	172	71.1	70	28.9	242	100.0	15.6
Colon	C18	3 720	1 641	44.1	2 079	55.9	3 720	100.0	54.5
Rectum	C19-20	3 715	1 743	46.9	1 972	53.1	3 715	100.0	53.2
Anus	C21	313	233	74.4	80	25.6	313	100.0	16.2
Liver	C22	9 872	8 208	83.1	1 664	16.9	9 872	100.0	6.2
Gall bladder	C23-24	2 293	1 779	77.6	514	22.4	2 293	100.0	9.1
Pancreas	C25	1 807	1 572	87.0	235	13.0	1 807	100.0	4.8
Gastrointestinal tract	C26	58	47	81.0	11	19.0	58	100.0	4.6
Nose/Sinuses	C30-31	224	126	56.3	98	43.8	224	100.0	47.9
Larynx	C32	791	320	40.5	471	59.5	791	100.0	58.5
Lung	C33-34	8 482	7 166	84.5	1 316	15.5	8 482	100.0	8.3
Other thoracic organs	C37-38	226	122	54.0	104	46.0	226	100.0	34.0
Bone	C40-41	343	186	54.2	157	45.8	343	100.0	44.9
Melanoma of skin	C43	179	96	53.6	83	46.4	179	100.0	50.6
Other skin	C44	618	131	21.2	487	78.8	618	100.0	68.7
Mesothelioma	C45	52	33	63.5	19	36.5	52	100.0	23.4
Connective tissue	C47+C49	484	228	47.1	256	52.9	484	100.0	53.7
Peritoneum	C48	160	102	63.8	58	36.3	160	100.0	28.3
Breast	C50	5 355	1 298	24.2	4 057	75.8	5 355	100.0	66.5
Vulva	C51	55	22	40.0	33	60.0	55	100.0	52.8
Vagina	C52	46	16	34.8	30	65.2	46	100.0	65.8
Cervix	C53	5 357	1 342	25.1	4 015	74.9	5 357	100.0	67.5
Corpus uteri	C54	522	99	19.0	423	81.0	522	100.0	72.2
Uterus unspecified	C55	87	26	29.9	61	70.1	87	100.0	67.2
Ovary	C56	1 305	483	37.0	822	63.0	1 305	100.0	58.3
Other female genital org.	C57	85	51	60.0	34	40.0	85	100.0	22.9
Placenta	C58	113	8	7.1	105	92.9	113	100.0	81.5
Penis	C60	43	16	37.2	27	62.8	43	100.0	61.0
Prostate	C61	948	460	48.5	488	51.5	948	100.0	53.6
Testis	C62	106	11	10.4	95	89.6	106	100.0	75.9
Kidney	C64	1 177	444	37.7	733	62.3	1 177	100.0	59.4
Renal pelvis	C65	147	53	36.1	94	63.9	147	100.0	61.4
Ureter	C66	104	51	49.0	53	51.0	104	100.0	55.8
Urinary bladder	C67	1 930	712	36.9	1 218	63.1	1 930	100.0	60.4
Other urinary organs	C68	64	42	65.6	22	34.4	64	100.0	19.3
Eye	C69	93	31	33.3	62	66.7	93	100.0	65.9
Brain & nervous system	C70-72	1 163	721	62.0	442	38.0	1 163	100.0	21.2
Thyroid	C73	2 657	229	8.6	2 428	91.4	2 657	100.0	72.0
Adrenal gland	C74	87	54	62.1	33	37.9	87	100.0	32.7
Other endocrine	C75	78	29	37.2	49	62.8	78	100.0	60.6
Hodgkin lymphoma	C81	133	40	30.1	93	69.9	133	100.0	63.6
Non-Hodgkin lymphoma	C82-85+C96	1 680	799	47.6	881	52.4	1 680	100.0	52.7
Multiple myeloma	C90	347	257	74.1	90	25.9	347	100.0	24.1
Lymphoid leukaemia	C91	595	352	59.2	243	40.8	595	100.0	27.6
Myeloid leukaemia	C92-94	1 219	915	75.1	304	24.9	1 219	100.0	13.6
Leukaemia unspecified	C95	80	68	85.0	12	15.0	80	100.0	5.7

FU: follow-up

Table 3. Comparison of 1-, 3- and 5-year absolute and relative survival and 5-year age-standardized relative survival by site: Seoul, Republic of Korea, 1993–1997 cases followed-up until 2001

Site	ICD-10	Cases included	% Absolute survival			% Relative survival			% ASRS at 5-years	
			1-year	3-year	5-year	1-year	3-year	5-year	all ages	0-74 years
Lip	C00	26	76.9	53.8	50.0	80.3	61.1	61.8	65.5	71.6
Tongue	C01-02	243	79.0	59.7	54.4	80.8	63.7	61.0	60.8	59.6
Oral cavity	C03-06	303	73.3	50.2	45.7	74.9	53.4	50.6	49.9	51.6
Salivary gland	C07-08	194	89.2	70.6	64.3	90.4	73.6	68.7	62.7	64.4
Tonsil	C09	92	77.2	56.5	51.9	78.6	59.6	56.6	55.0	58.3
Oropharynx	C10	52	67.3	40.4	32.7	68.9	42.8	35.7	37.0	42.8
Nasopharynx	C11	278	81.7	52.5	43.7	82.7	54.4	46.3	41.3	47.1
Hypopharynx	C12-13	170	56.5	28.2	25.1	58.0	30.7	29.3	31.3	31.3
Oesophagus	C15	1 134	42.3	20.4	16.8	43.6	22.1	19.2	20.0	22.8
Stomach	C16	16 180	64.2	47.3	42.9	65.6	50.2	47.6	43.3	49.2
Small intestine	C17	242	55.4	36.4	30.0	56.5	38.3	32.8	29.6	34.5
Colon	C18	3 720	77.1	62.2	56.8	78.9	66.7	64.1	59.8	65.7
Rectum	C19-20	3 715	82.5	61.8	54.3	84.2	65.8	60.6	57.5	61.5
Anus	C21	313	56.2	34.2	28.0	57.8	37.3	32.4	31.5	33.8
Liver	C22	9 872	38.7	21.9	17.5	39.4	23.1	19.2	18.9	20.3
Gall bladder	C23-24	2 293	44.3	27.3	23.0	45.5	29.5	26.4	27.9	30.3
Pancreas	C25	1 807	26.1	14.4	13.1	26.8	15.6	15.0	15.6	17.1
Gastrointestinal tract	C26	58	41.4	27.6	22.3	42.7	30.3	26.2	26.2	27.0
Nose/Sinuses	C30-31	224	74.1	54.0	45.9	75.3	56.9	50.4	53.1	50.9
Larynx	C32	791	83.1	65.7	61.5	85.5	71.8	71.8	71.0	75.6
Lung	C33-34	8 482	40.2	18.6	15.9	41.4	20.3	18.5	18.1	19.7
Other thoracic organs	C37-38	226	67.3	49.6	46.3	68.3	51.6	49.4	39.1	47.1
Bone	C40-41	343	73.5	53.6	46.3	74.1	54.9	48.1	39.2	39.8
Melanoma of skin	C43	179	81.0	56.4	48.1	82.4	59.6	52.8	52.6	49.5
Other skin	C44	618	91.3	83.2	80.0	93.9	90.8	93.2	93.4	92.6
Mesothelioma	C45	52	61.5	44.2	40.4	62.5	46.0	43.4	43.8	40.8
Connective tissue	C47+C49	484	79.5	61.0	53.8	80.6	63.2	57.2	50.8	55.7
Peritoneum	C48	160	65.6	46.3	38.4	66.5	47.7	40.4	30.4	41.2
Breast	C50	5 355	94.0	82.7	77.7	94.5	84.0	79.8	74.4	78.6
Vulva	C51	55	90.9	65.5	60.0	92.4	69.2	66.4	67.8	69.3
Vagina	C52	46	82.6	71.7	67.2	83.8	74.3	71.1	62.5	75.6
Cervix	C53	5 357	91.3	79.6	75.7	92.0	81.4	78.7	76.2	79.2
Corpus uteri	C54	522	93.9	85.2	81.8	94.5	87.0	84.7	78.8	81.7
Uterus unspecified	C55	87	86.2	77.0	73.6	87.0	78.7	76.4	68.7	77.8
Ovary	C56	1 305	84.3	69.3	64.2	84.9	70.7	66.2	57.8	62.2
Other female genital org.	C57	85	57.6	45.9	41.2	58.2	47.3	43.2	38.9	40.1
Placenta	C58	113	96.5	94.7	92.8	96.6	95.0	93.3	95.3	95.3
Penis	C60	43	88.4	76.7	64.9	92.0	87.9	82.2	85.8	77.5
Prostate	C61	948	85.4	64.0	53.5	90.3	76.3	72.8	74.4	70.2
Testis	C62	106	96.2	92.5	91.5	96.6	93.7	93.7	94.9	93.9
Kidney	C64	1 177	80.6	67.9	63.0	82.1	71.6	68.9	63.5	70.3
Renal pelvis	C65	147	84.4	70.7	65.1	86.3	76.4	74.9	77.4	71.1
Ureter	C66	104	85.6	60.6	54.4	87.8	65.7	63.1	57.5	57.5
Urinary bladder	C67	1 930	85.5	70.7	64.2	88.3	77.9	75.7	70.9	79.5
Other urinary organs	C68	64	54.7	40.6	34.1	57.1	46.7	42.8	42.1	44.3
Eye	C69	93	86.0	72.0	67.7	86.7	73.8	70.5	62.2	58.1
Brain & nervous system	C70-72	1 163	62.9	42.5	39.2	63.4	43.3	40.4	37.1	38.9
Thyroid	C73	2 657	95.7	93.7	91.6	96.4	95.6	94.7	92.8	94.4
Adrenal gland	C74	87	67.8	46.0	40.8	68.2	46.6	41.7	23.1	31.6
Other endocrine	C75	78	80.8	64.1	62.7	81.7	65.6	64.7	37.7	50.4
Hodgkin lymphoma	C81	133	85.7	75.2	71.2	86.5	77.1	74.4	75.3	76.3
Non-Hodgkin lymphoma	C82-85+C96	1 680	71.3	57.4	53.5	72.3	59.6	57.0	56.7	58.0
Multiple myeloma	C90	347	65.1	38.3	27.4	66.4	40.6	30.1	29.4	32.0
Lymphoid leukaemia	C91	595	67.1	46.4	41.8	67.4	46.8	42.5	33.8	38.5
Myeloid leukaemia	C92-94	1 219	54.5	31.8	25.8	54.9	32.5	26.6	22.7	26.3
Leukaemia unspecified	C95	80	28.8	17.5	14.8	29.2	18.1	15.3	13.8	16.8

ASRS: age-standardized relative survival

Table 4a. Site-wise number of cases, 5-year absolute and relative survival by sex: Seoul, Republic of Korea, 1993–1997 cases followed-up until 2001

Site	ICD-10	Cases included	Male			Female		
			% 5-year survival			% 5-year survival		
			No.	Abs	Rel	No.	Abs	Rel
Lip	C00	26	14	50.0	65.0	12	50.0	58.8
Tongue	C01-02	243	163	52.5	59.8	80	58.3	63.4
Oral cavity	C03-06	303	221	38.8	44.1	82	64.2	67.7
Salivary gland	C07-08	194	109	54.9	60.2	85	76.3	79.4
Tonsil	C09	92	74	50.0	55.1	18	60.7	63.9
Oropharynx	C10	52	42	33.3	36.4	10	30.0	32.6
Nasopharynx	C11	278	204	37.5	40.4	74	60.8	62.4
Hypopharynx	C12-13	170	159	24.3	28.7	11	36.4	37.8
Oesophagus	C15	1 134	995	15.5	17.8	139	25.9	28.9
Stomach	C16	16 180	10 439	43.1	48.5	5 741	42.7	45.9
Small intestine	C17	242	143	27.9	31.2	99	33.0	35.2
Colon	C18	3 720	1 985	59.4	68.5	1 735	53.8	59.1
Rectum	C19-20	3 715	2 091	52.9	60.3	1 624	56.0	60.9
Anus	C21	313	138	21.5	26.1	175	33.1	37.2
Liver	C22	9 872	7 553	16.9	18.7	2 319	19.4	20.8
Gall bladder	C23-24	2 293	1 127	24.3	28.5	1 166	21.8	24.4
Pancreas	C25	1 807	993	11.8	13.8	814	14.7	16.3
Gastrointestinal tract	C26	58	35	16.9	20.1	23	30.4	35.4
Nose/Sinuses	C30-31	224	142	40.8	45.3	82	54.6	59.0
Larynx	C32	791	717	62.5	73.0	74	52.3	59.9
Lung	C33-34	8 482	6 197	15.4	18.1	2 285	17.5	19.5
Other thoracic organs	C37-38	226	138	42.6	45.6	88	52.1	55.3
Bone	C40-41	343	200	43.7	45.7	143	49.9	51.3
Melanoma of skin	C43	179	87	40.7	45.1	92	55.0	60.0
Other skin	C44	618	328	75.8	88.6	290	84.8	98.4
Mesothelioma	C45	52	32	37.5	39.9	20	45.0	49.0
Connective tissue	C47+C49	484	261	50.6	54.5	223	57.6	60.3
Peritoneum	C48	160	82	42.1	44.5	78	34.5	35.9
Breast	C50	5 355	35	60.0	68.7	5 320	77.8	79.9
Vulva	C51	55				55	60.0	66.4
Vagina	C52	46				46	67.2	71.1
Cervix	C53	5 357				5 357	75.7	78.7
Corpus uteri	C54	522				522	81.8	84.7
Uterus unspecified	C55	87				87	73.6	76.4
Ovary	C56	1 305				1 305	64.2	66.2
Other female genital org.	C57	85				85	41.2	43.2
Placenta	C58	113				113	92.8	93.3
Penis	C60	43	43	64.9	82.2			
Prostate	C61	948	948	53.5	72.8			
Testis	C62	106	106	91.5	93.7			
Kidney	C64	1 177	781	61.2	68.0	396	66.5	70.6
Renal pelvis	C65	147	103	70.6	81.6	44	52.3	59.5
Ureter	C66	104	70	52.1	62.0	34	58.8	64.8
Urinary bladder	C67	1 930	1 595	65.4	77.6	335	58.6	66.8
Other urinary organs	C68	64	33	36.1	49.0	31	32.3	36.4
Eye	C69	93	58	69.0	72.1	35	65.7	67.8
Brain & nervous system	C70-72	1 163	643	37.5	38.9	520	41.3	42.2
Thyroid	C73	2 657	416	84.2	90.2	2 241	93.0	95.5
Adrenal gland	C74	87	50	41.0	42.2	37	40.4	40.8
Other endocrine	C75	78	56	62.5	64.9	22	63.3	64.3
Hodgkin lymphoma	C81	133	75	63.6	66.9	58	81.0	84.1
Non-Hodgkin lymphoma	C82-85+C96	1 680	986	50.8	54.9	694	57.2	60.0
Multiple myeloma	C90	347	196	24.7	28.0	151	31.0	32.7
Lymphoid leukaemia	C91	595	343	37.4	38.1	252	47.9	48.4
Myeloid leukaemia	C92-94	1 219	671	26.8	27.9	548	24.5	25.0
Leukaemia unspecified	C95	80	40	12.5	13.2	40	16.9	17.2

Abs: absolute survival; Rel: relative survival

Table 4b. Site-wise number of cases and relative survival by age group: Seoul, Republic of Korea, 1993–1997 cases followed-up until 2001

Site	ICD-10	Cases included	Number of cases by age group					Relative survival by age group				
			< 45 45-54 55-64 65-74 > 75					% 5-year survival				
			< 45	45-54	55-64	65-74	> 75	< 45	45-54	55-64	65-74	> 75
Lip	C00	26	2	3	4	6	11	100.5	33.9	82.3	78.5	44.3
Tongue	C01-02	243	39	53	74	49	28	83.1	60.4	55.7	45.5	77.0
Oral cavity	C03-06	303	50	59	97	64	33	83.0	43.5	47.0	42.9	38.3
Salivary gland	C07-08	194	62	54	42	23	13	84.4	63.0	72.0	35.2	64.5
Tonsil	C09	92	13	25	29	19	6	85.8	58.3	59.2	31.5	51.3
Oropharynx	C10	52	8	13	11	13	7	63.3	32.0	49.0	28.1	0.0
Nasopharynx	C11	278	98	72	64	32	12	57.7	54.4	23.2	41.6	37.1
Hypopharynx	C12-13	170	5	33	59	57	16	40.8	35.0	24.2	29.0	38.2
Oesophagus	C15	1 134	24	169	448	336	157	42.2	19.7	23.0	15.1	12.5
Stomach	C16	16 180	2 728	3 154	4 715	3 769	1 814	52.7	55.5	50.9	41.0	29.7
Small intestine	C17	242	45	44	70	55	28	42.8	37.6	36.7	24.2	16.0
Colon	C18	3 720	478	702	1 059	948	533	69.5	67.3	67.4	62.2	51.0
Rectum	C19-20	3 715	495	774	1 119	895	432	59.8	63.0	62.9	60.6	52.0
Anus	C21	313	39	60	73	68	73	20.7	37.4	35.0	36.4	27.5
Liver	C22	9 872	1 309	2 918	3 159	1 802	684	25.3	18.8	18.8	18.3	13.1
Gall bladder	C23-24	2 293	151	346	662	668	466	42.9	30.0	26.5	23.9	22.0
Pancreas	C25	1 807	138	273	544	521	331	32.7	17.1	10.7	14.9	13.4
Gastrointestinal tract	C26	58	7	6	14	18	13	14.4	48.9	15.6	32.9	24.4
Nose/Sinuses	C30-31	224	53	60	55	37	19	46.7	49.9	44.9	60.4	61.4
Larynx	C32	791	33	131	302	214	111	80.0	79.9	71.6	74.4	53.8
Lung	C33-34	8 482	482	1 218	2 504	2 788	1 490	23.5	23.6	20.1	15.8	14.9
Other thoracic organs	C37-38	226	86	38	41	44	17	64.3	54.7	37.0	37.4	16.6
Bone	C40-41	343	227	30	42	27	17	52.0	58.5	47.9	9.0	38.1
Melanoma of skin	C43	179	42	40	49	28	20	37.2	56.6	60.9	50.0	66.5
Other skin	C44	618	113	94	131	149	131	86.8	90.1	93.7	98.7	97.0
Mesothelioma	C45	52	13	14	12	8	5	46.8	44.4	44.2	30.2	53.7
Connective tissue	C47+C49	484	227	78	77	64	38	61.5	65.9	54.2	45.1	35.5
Peritoneum	C48	160	61	34	35	20	10	50.7	32.9	40.0	41.4	0.0
Breast	C50	5 355	2 107	1 814	922	387	125	81.6	82.0	77.7	71.3	56.5
Vulva	C51	55	10	8	11	19	7	60.4	63.5	84.7	59.1	68.0
Vagina	C52	46	10	11	11	9	5	80.4	72.8	85.3	64.0	26.7
Cervix	C53	5 357	1 794	1 373	1 262	711	217	87.1	79.4	75.4	68.3	52.9
Corpus uteri	C54	522	158	169	126	51	18	90.9	88.3	78.9	72.4	71.4
Uterus unspecified	C55	87	35	21	13	12	6	77.6	82.2	95.9	57.0	45.5
Ovary	C56	1 305	572	287	242	139	65	81.5	64.1	52.2	44.1	35.5
Other female genital org.	C57	85	26	22	17	15	5	54.2	46.2	42.7	21.8	33.1
Placenta	C58	113	99	13	1	0	0	94.2	85.9	102.7		
Penis	C60	43	4	6	11	11	11	101.8	69.4	50.4	89.7	112.2
Prostate	C61	948	9	25	193	365	356	33.7	57.7	74.0	71.2	77.3
Testis	C62	106	90	8	3	4	1	91.8	104.5	109.9	91.9	150.5
Kidney	C64	1 177	240	258	353	229	97	80.9	75.8	68.7	58.3	42.6
Renal pelvis	C65	147	10	29	44	51	13	61.0	64.5	81.4	73.8	96.8
Ureter	C66	104	3	21	29	36	15	34.1	44.2	74.8	69.6	57.2
Urinary bladder	C67	1 930	184	302	541	516	387	92.7	84.9	76.8	75.0	57.3
Other urinary organs	C68	64	3	7	16	14	24	33.6	59.0	40.4	50.4	35.8
Eye	C69	93	62	12	12	3	4	69.7	60.4	98.6	0.0	79.5
Brain & nervous system	C70-72	1 163	651	169	205	106	32	51.9	34.7	25.0	14.3	14.0
Thyroid	C73	2 657	1 348	560	424	234	91	99.6	97.1	93.1	79.9	44.7
Adrenal gland	C74	87	62	10	11	3	1	43.0	51.8	39.7	0.0	0.0
Other endocrine	C75	78	53	6	10	4	5	73.7	86.4	54.4	0.0	0.0
Hodgkin lymphoma	C81	133	76	20	17	17	3	83.3	72.4	50.7	62.8	57.3
Non-Hodgkin lymphoma	C82-85+C96	1 680	608	335	378	264	95	62.6	58.8	56.0	46.4	49.5
Multiple myeloma	C90	347	39	71	111	95	31	56.7	27.1	30.1	27.4	7.6
Lymphoid leukaemia	C91	595	483	34	33	36	9	46.1	18.1	25.2	39.2	14.2
Myeloid leukaemia	C92-94	1 219	701	187	178	113	40	33.1	20.9	20.9	10.4	7.2
Leukaemia unspecified	C95	80	41	10	10	10	9	29.4	0.0	0.0	0.0	0.0